WHAT IS CLAIMED IS:

1. Use of methylone (3,4-methylenedioxy-N-methylcathinone) in the manufacture of a medicament for the treatment and/or the prevention of a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof.

2. The use of claim 1, wherein the methylone is to be administered in a dose of 50-1,000 mg.

3. The use of claim 1, wherein the methylone is to be administered in a dose of 0.8-30 mg/kg.

4. The use of any one of claims 1 to 3, wherein the subject is suicidal.

5. The use of any one of claims 1 to 4, wherein the methylone is used in combination with an additional therapy for the neuropsychiatric illness.

6. The use of claim 5, wherein the additional therapy is psychotherapy.

7. The use of claim 5, wherein the additional therapy comprises one or more additional psychoactive agents to be administered to the subject.

8. The use of claim 7, wherein the additional psychoactive agents are selected from the group consisting of selective-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRIs), and anxiolytic agents.

9. The use of claim 8, wherein the additional psychoactive agent is a selective-serotonin reuptake inhibitor (SSRI).

10. The used of claim 9, wherein the SSRI is taken concurrently with the methylone.

11. The use of any one of claims 1 to 10, wherein the neuropsychiatric illness is post-traumatic stress disorder (PTSD).

12. The use of claim 11, wherein the PTSD is treatment-resistant.

13. The use of claim 1, wherein the neuropsychiatric illness is acute stress disorder.

14. The use of claim 1, wherein the neuropsychiatric illness is a Depressive Disorder.

15. The use of claim 14, wherein the Depressive Disorder is selected from the group consisting of Disruptive Mood Dysregulation Disorder, Major Depressive Disorder, Single and Recurrent Episodes, Persistent Depressive Disorder (Dysthymia),

Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, and combinations thereof.

16. The use of claim 14 or claim 15, wherein the Depressive Disorder is treatment-resistant.

17. The use of claim 1, wherein the neuropsychiatric illness is a Personality Disorder (PD).

18. The use of claim 17, wherein the Personality Disorder is selected from the group consisting of Borderline Personality Disorder (BPD), Avoidant Personality Disorder (AvPD), Antisocial Personality Disorder (AsPD), Schizotypal Personality Disorder, Other Anxiety and Panic producing Disorders, Specific personality disorders, Impulse disorders, Gender identity disorders, Paraphilias, Other sexual disorders, Other disorders of adult personality and behavior, Unspecified disorder of adult personality and behavior, Personality and behavioral disorders due to known physiological conditions.

19. The use of claim 18, wherein the subject has a Depressive Disorder.

20. The use of any one of claims 17 to 19, wherein the PD is treatment-resistant.

21. The use of claim 1, wherein the neuropsychiatric illness is an Anxiety Disorder.

22. The use of claim 21, wherein the Anxiety Disorder is selected from the group consisting of Generalized anxiety disorder, Panic disorder, Panic attack, Phobic anxiety disorders, Illness Anxiety Disorder, dissociative, stress-related, somatoform other nonpsychotic mental disorders, acute stress reaction, transient adjustment reaction, neurasthenia, psychophysiologic disorders, Obsessive-compulsive disorder, Reaction to severe stress and adjustment disorders, Separation Anxiety Disorder, episodic paroxysmal anxiety, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Agoraphobia, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical Condition, Anxiety in pregnancy and childbirth, Anxiety in pregnancy antepartum (before childbirth), Anxiety postpartum, Animal type phobia, Arachnophobia, Other animal type phobia, Natural environment type phobia, Fear of thunderstorms, Fear of blood, Fear of injections and transfusions, Fear of other medical care, Fear of injury, Situational type phobia, Claustrophobia, Acrophobia, Other Unspecified Anxiety Disorder, Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-Picking), and combinations thereof.

23. The use of claim 1, wherein the neuropsychiatric illness is a mood disorder.

24. The use of claim 1, wherein the neuropsychiatric illness is Fibromyalgia.

25. The use of claim 1, wherein the neuropsychiatric illness is an eating disorder.

26. The use of any one of claims 1 to 25, wherein the methylone is to be administered weekly.

27. The use of any one of claims 1 to 26, wherein an initial dose of methylone is to be administered, which is then boosted by a second methylone dose to be administered 30 minutes-4 hours later in an amount that is about 10% -100% of the initial dose.